Indications for percutaneous left atrial appendage occlusion in hospitalized patients with atrial fibrillation.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
pubmed:
29
9
2021
medline:
15
3
2022
entrez:
28
9
2021
Statut:
ppublish
Résumé
Percutaneous left atrial appendage occlusion (LAAO) is an alternative nonpharmacological therapeutic option for stroke prevention in patients with NVAF. However, no data exist on potential LAAO candidates' prevalence among 'real-world' NVAF patients. This study aimed to investigate the indications for LAAO in hospitalized patients with comorbid nonvalvular atrial fibrillation (NVAF). This is a post-hoc analysis of the MISOAC-AF (Motivational Interviewing to Support OAC-AF, ClinicalTrials.gov: NCT02941978), randomized controlled trial, which enrolled NVAF patients hospitalized for any reason in a tertiary cardiology department. In this analysis, patients with a history of major bleeding or stroke under OAC therapy were considered to have a strong indication for LAAO. A total of 980 patients with NVAF were studied (mean age 73.9 ± 10.9 years, 54.7% men). Prior major bleeding occurred in 134 (13.7%) patients (intracranial bleeding in 1%, upper and lower gastrointestinal bleeding in 6.4 and 8.9%, respectively). A total of 58 (5.9%) patients experienced an embolic stroke while being treated using OAC. Overall, either of these events was prevalent in 173 (17.7%) patients, denoting a strong indication for LAAO. Almost one out of six patients hospitalized with comorbid NVAF may be considered eligible for percutaneous LAAO for stroke prevention.Trial Identification: NCT02941978, https://clinicaltrials.gov/ct2/show/NCT02941978.
Identifiants
pubmed: 34580251
doi: 10.2459/JCM.0000000000001226
pii: 01244665-202203000-00005
doi:
Banques de données
ClinicalTrials.gov
['NCT02941978']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
176-182Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; 42:373–498.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071–3104.
Kartas A, Samaras A, Vasdeki D, et al. Flaws in anticoagulation strategies in patients with atrial fibrillation at hospital discharge. J Cardiovasc Pharmacol Ther 2019; 24:225–232.
Obamiro KO, Chalmers L, Lee K, Bereznicki BJ, Bereznicki LR. Adherence to oral anticoagulants in atrial fibrillation: an Australian survey. J Cardiovasc Pharmacol Ther 2018; 23:337–343.
Lowres N, Giskes K, Hespe C, Freedman B. Reducing stroke risk in atrial fibrillation: adherence to guidelines has improved, but patient persistence with anticoagulant therapy remains suboptimal. Korean Circ J 2019; 49:883–907.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–867.
Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61:755–759.
Tzikas A, Holmes DR, Gafoor S, et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. EuroIntervention 2016; 12:103–111.
Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update. Europace 2020; 22:184.
Ellis CR, Jackson GG. When to refer patients for left atrial appendage closure. Card Electrophysiol Clin 2020; 12:29–37.
Samaras A, Kartas A, Vasdeki D, et al. Rationale and design of a randomized study comparing Motivational Interviewing to Support Oral AntiCoagulation adherence versus usual care in patients with nonvalvular Atrial Fibrillation: the MISOAC-AF trial. Hellenic J Cardiol 2020; 61:453–454.
Tzikas A, Samaras A, Kartas A, et al. Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with nonvalvular Atrial Fibrillation (MISOAC-AF): a randomized clinical trial. Eur Hear J Cardiovasc Pharmacother 2020; 7:f63–f71.
Steffel J, Verhamme P, Potpara TS, et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39:1330–1393.
Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137:263–272.
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093–1100.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31–41.
Calkins H, Gliklich RE, Leavy MB, et al. Harmonized outcome measures for use in atrial fibrillation patient registries and clinical practice: endorsed by the Heart Rhythm Society Board of Trustees. Hear Rhythm 2019; 16:e3–e16.
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005; 3:692–694.
Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25:2303–2310.
Crivera C, Nelson WW, Bookhart B, et al. Pharmacy quality alliance measure: adherence to nonwarfarin oral anticoagulant medications. Curr Med Res Opin 2015; 31:1889–1895.
Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 2011; 123:2736–2747.
Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fi brillation: a randomised noninferiority trial. Lancet 2009; 374:534–542.
Freixa X, Abualsaud A, Chan J, et al. Left atrial appendage occlusion: initial experience with the AmplatzerTM AmuletTM. Int J Cardiol 2014; 174:492–496.
Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention 2016; 11:1170–1179.
Holmes DR, Lakkireddy DR, Whitlock RP, Waksman R, Mack MJ. Left atrial appendage occlusion: opportunities and challenges. J Am Coll Cardiol 2014; 63:291–298.
Kourlaba G, Stefanou G, Tsalamandris S, et al. Incidence and cost of bleeding events requiring hospitalization in patients with atrial fibrillation treated with acenocoumarol in Greece. Hell J Cardiol 2020.
Yang E. A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution? Vasc Health Risk Manag 2014; 10:507–522.
Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol 2018; 14:337–351.
Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705–711.
Reinecke H, Engelbertz C, Schäbitz WR. Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants. Stroke 2013; 44:2935–2941.
Tzikas A, Freixa X, Llull L, et al. Patients with intracranial bleeding and atrial fibrillation treated with left atrial appendage occlusion: results from the Amplatzer Cardiac Plug registry. Int J Cardiol 2017; 236:232–236.
Cruz-González I, González-Ferreiro R, Freixa X, et al. Left atrial appendage occlusion for stroke despite oral anticoagulation (resistant stroke): results from the Amplatzer Cardiac Plug registry. Rev Española Cardiol (Engl Ed) 2020; 73:28–34.
Lee OH, Kim YD, Kim JS, et al. Favorable neurological outcome after ischemic cerebrovascular events in patients treated with percutaneous left atrial appendage occlusion compared with warfarin. Catheter Cardiovasc Interv 2019; 94:E23–E29.
Kefer J, Tzikas A, Freixa X, et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Int J Cardiol 2016; 207:335–340.
Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart 2020; 106:119–126.
Salmasi S, Loewen PS, Tandun R, Andrade JG, De Vera MA. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ Open 2020; 10:1–14.
Cresti A, García-Fernández MA, Sievert H, et al. Prevalence of extra-appendage thrombosis in nonvalvular atrial fibrillation and atrial flutter in patients undergoing cardioversion: a large transoesophageal echo study. EuroIntervention 2019; 15:e225–e230.
Thakkar J, Vasdeki D, Tzikas A, Meier B, Saw J. Incidence, prevention, and management of periprocedural complications of left atrial appendage occlusion. Interv Cardiol Clin 2018; 7:243–252.